CHEK2 and non-Hodgkin lymphoma: Five out of 340 NHL patients (1.5%) carried a variant truncating the CHK2 protein sequence, in all cases upstream of the kinase domain, similarly to the 1100delC alteration (a well-known pathogenic mutation increasing the risk of various solid cancers).